Enhancing the efficacy of EBC-46 in the treatment of head and neck squamous cell carcinoma

Optimising intratumoural treatment of head and neck squamous cell carcinoma mouse models with EBC-46

“…In nude mice, a single bolus dose of 30 µg EBC-46 in 50 µl 40% PG to an SCC-15 tumour site led to an 70% long term ablation rate, confirming the potential of EBC-46 for local treatment of HNSCC, but lower than ablation rates obtained with the FaDu and Cal27 xenografts [91]. In NOD/SCID mice, dividing the dose of the compound into multiple injections of the same tumor did not improve survival, nor was further reduction in tumour growth found with the use of 2-hydroxypropyl-β-cyclodextrin as an excipient.…”